Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8641652 | 0.69 | — | — | |
| SCHEMBL28557426 | 0.69 | CTH (0.38) | CYP1A2CYP2D6HSD17B10 | |
| SCHEMBL25438034 | 0.65 | CYP1A2 (0.45) | CYP1A2CYP2D6HSD17B10HIF1AFFAR3 | |
| SCHEMBL5678982 | 0.65 | — | — | |
| SCHEMBL17489047 | 0.63 | CYP1A2 (0.39) | CYP1A2CYP2D6HSD17B10HIF1AFFAR3 | |
| SCHEMBL28928396 | 0.63 | HSD17B10 (0.39) | CYP1A2CYP2D6HSD17B10HIF1AFFAR3 | |
| SCHEMBL4997664 | 0.63 | — | — | |
| SCHEMBL20274640 | 0.63 | — | — | |
| SCHEMBL742517 | 0.61 | — | — | |
| Guanidino Acetate SCHEMBL7467126 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021081110-A2 | PEPTIDES AND USE THEREOF | ANEXIGEN, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| US-9540620-B2 | Methods and compositions for modulating G-alpha-Q signaling | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150218538-A1 | Methods and Compositions for Modulating G-Alpha-Q Signaling | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-06 | — | — | US | disclosed |
| US-6720433-B2 | MOTILIN RECEPTOR ANTAGONIST; PHE-N-ME-VAL-(3-(3-METHYLINDOL-5-YL))ALA-NH2;PHE-N-ME-VAL-PHE( 3-ACETYL-4-HYDROXY)-NH2;PHE-N-ME-VAL-(3-(5-TERT-BUTYL-4-SULFAM OYL-2-FURYL))ALA-NH2 | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20030176643-A1 | Ethylamine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-09-18 | — | — | US | disclosed |
| US-6586630-B1 | Carbocyclic carboxy amines, used as motilin receptor antagonists for therapy of gastrointerstinal disorders such as irritable bowel syndrome; hormone inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-01 | — | — | US | disclosed |
| EP-1116726-A1 | ETHYLAMINE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176643-A1 | Ethylamine derivatives | MLNR, GIPR, MC4R | CYP1A2 3223/4885CYP2D6 1948/4885HSD17B10 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.